The University of Cambridge has announced four new collaborations with AstraZeneca and its global biologics research and development arm, MedImmune.
The existing strategic partnership between the University of Cambridge, AstraZeneca and MedImmune includes a substantial oncology research programme and co-location of AstraZeneca scientists at the Cancer Research UK Cambridge Institute, the largest single facility conducting cancer research in the University of Cambridge.
Patrick Maxwell, Regius Professor, University of Cambridge’s School of Clinical Medicine, says: “These exciting new collaborations will strengthen even further the strategic partnership between the University of Cambridge and AstraZeneca ahead of the company’s relocation to the Cambridge Biomedical Campus. This Campus is the centrepiece of the largest biotech cluster outside the United States, a truly world class environment in which to conduct research aimed at transforming the lives of patients.”
The four agreements involve:
A three-year collaboration between the University, AstraZeneca and MedImmune will focus on advancing research and development in neurodegenerative diseases, an area with a large unmet medical need.
Access to AstraZeneca pipeline compounds
A pivotal Material Transfer Agreement will enable investigators from the University of Cambridge to access key compounds from AstraZeneca’s pipeline for investigation.
PhD programme to support future leaders in science
A collaboration between the University of Cambridge and MedImmune will include a doctoral training programme whereby PhD candidates will spend significant time at the University of Cambridge and in MedImmune’s laboratories, jointly supervised by the organisations during their four-year studentship.
This programme will offer guidance and mentorship to academic researchers at the University of Cambridge who are considering the broader application and commercial potential of their scientific programmes.
For more information go to: http://www.cam.ac.uk/news/astrazeneca-and-university-of-cambridge-strengthen-long-standing-partnership